BioInvent & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade
20.01.2022 - LUND, SWEDEN / ACCESSWIRE / January 20, 2022 / BioInvent International (STO:BINV)Preclinical proof-of-concept data published in the January 20, 2022 edition of the Journal for ImmunoTherapy of Cancer (JITC)BioInvent International AB ('BioInvent') ... Seite 1
Source: wallstreet-online.de